Search clinical trials for: IW

Total 32 results

Rigshospitalet, Denmark

Unknown

Optimization of Interval-training in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Denmark
Cyclerion Therapeutics

Completed

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Terminated

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Dyspepsia | Functional Gastrointestinal Disorders

Belgium, Netherlands
Tisento Therapeutics
Children's Hospital of Philadelphia

Terminated

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

MELAS

United States
Cyclerion Therapeutics

Terminated

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Achalasia

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

Healthy Volunteers

United States
Rigshospitalet, Denmark

Unknown

Interval-training and Appetite Regulation in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Denmark
Tisento Therapeutics

Terminated

IW-6463 Safety Study in Healthy Elderly Subjects

Other

Netherlands
Tisento Therapeutics

Completed

A Study of IW-6463 in Healthy Volunteers

Other

Netherlands
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD)

Sickle Cell Disease

United States, United Kingdom, Lebanon
Cyclerion Therapeutics

Completed

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

Diabetic Gastroparesis

United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Recruiting

Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis | Bladder Pain Syndrome

United States
University of Colorado, Denver

Completed

Compression and Cold Therapy on the Post-Operative Shoulder

Postoperative Pain | Shoulder Pain

United States
Ironwood Pharmaceuticals, Inc.

Completed

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Gastroesophageal Reflux

United States
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

United States, Canada
University of Colorado, Denver

Completed

Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults (B-WELL)

Diabetes | Metabolic Syndrome | Aging

United States
Ironwood Pharmaceuticals, Inc.

Terminated

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

Canada, United States
Ironwood Pharmaceuticals, Inc.

Completed

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States
Assiut University

Not yet recruiting

Efficacy and Safety of Interwoven Self-Expandable Nitinol Stent for Femropopliteal Arterial Occlusive Diseases

Femoropopliteal Occlusive Disease

Egypt
Cyclerion Therapeutics

Completed

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Cyclerion Therapeutics

Completed

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
Cyclerion Therapeutics

Completed

Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Completed

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

Healthy

United States
Cyclerion Therapeutics

Completed

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers

Healthy

United States
Cyclerion Therapeutics

Completed

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Completed

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

Healthy Volunteers

United States

3

Subscribe